Ambroxol 30mg tablets 20
Women's clothing size
With your arms relaxed at your sides, measure around the fullest part of your chest.
Measure around the narrowest part of your natural waist, generally around the belly button. To ensure a comfortable fit, keep one finger between the measuring tape and your body.
1 tablet contains: ambroxol hydrochloride - 30 mg.
Excipients: lactose monohydrate - 171 mg, corn starch - 36 mg, silicon dioxide colloidal (aerosil) - 1.8 mg, magnesium stearate - 1.2 mg.
A mucolytic and expectorant, it is an active N-demethylated metabolite of bromhexine. It has a secretomotor, secretolytic and expectorant effect.
Stimulates serous cells of the bronchial mucosa, increases the motor activity of the cicatricial epithelium by acting on type 2 pneumocytes in the alveoli and Clara cells in the bronchioles, enhances the formation of endogenous surfactant - a surfactant that provides sliding of bronchial secretion in the lumen of the respiratory tract.
Ambroxol increases the proportion serous component in bronchial secretion, improving its structure and helping to reduce viscosity and liquefaction of sputum; as a result, mucocilic transport is improved and the removal of sputum from the bronchial tree is facilitated.
When taking ambroxol inside, the effect, on average, occurs after 30 minutes and lasts 6-12 hours, depending on the single dose.
After ingestion, ambroxol is quickly and almost completely absorbed. T max is 1-3 h. Binding to plasma proteins is approximately 85%.
Penetrates the placental barrier, excreted in breast milk. It is metabolized in the liver with the formation of metabolites (dibromanthranilic acid, glucuronic conjugates), which are excreted by the kidneys.
It is excreted mainly by the kidneys - 90% in the form of metabolites, less than 10% unchanged. T 1/2 of the plasma is 7-12 h. T 1/2 ambroxol and its metabolites are approximately 22 hours.
Due to high protein binding and large V d , as well as slow reverse penetration from the tissues into the blood, during dialysis or forced diuresis, there is no significant excretion of ambroxol.
The clearance of ambroxol in patients with severe hepatic insufficiency is reduced by 20-40%. In severe renal failure T 1/2 ambroxol metabolites increase.
Indications for use
Respiratory diseases, accompanied by the release of viscous sputum and difficulty in the discharge of sputum:
- acute and chronic bronchitis;
- bronchial asthma;
- Hypersensitivity to ambroxol or auxiliary components of drugs;
- I trimester of pregnancy;
- lactation (breastfeeding);
- congenital intolerance to fructose (for dosage forms containing fructose);
- children's age up to 6 years (for tablets);
- children's age up to 12 years (for capsules of prolonged action).
With caution: impaired bronchial motility and increased mucus secretion (for example, with a rare syndrome of immobile cilia); renal failure and / or severe liver failure; peptic ulcer of the stomach and duodenum (including in the anamnesis); II and III trimesters of pregnancy; children's age up to 2 years (oral solution; only as prescribed by a doctor).
Dosage and Administration
The duration of treatment is determined by the doctor individually and depends on the severity of the disease. If necessary, use the drug for more than 4-5 days a doctor's consultation is required.
Take inside after meals with a sufficient amount of liquid.
Adults and children over the age of 12 years: 30 mg 2-3 times / day for the first 2-3 days, then 30 mg 2 times / day.
Children aged 5 to 12 years: 30-45 mg / day in 2-3 doses.
Children aged 2 to 5 years: 22.5 mg / day in 3 doses.
Children under 2 years: 15 mg / day in 2 doses. The drug is prescribed only under the supervision of a doctor.
Treatment of children under the age of 2 years should be carried out only under the supervision of a doctor.
In patients with renal insufficiency and severe renal insufficiency, ambroxol should be used at longer intervals or in reduced doses.
Allergic reactions: rarely - skin rash, urticaria, exanthema, swelling of the face, shortness of breath, itching, fever; frequency unknown - anaphylactic reactions, including anaphylactic shock, angioedema, skin itching, allergic contact dermatitis.
From the digestive system: often - nausea; infrequently - vomiting, diarrhea, dyspepsia, abdominal pain.
From the nervous system: often - dysgeusia.
From the skin and subcutaneous tissues: very rarely - toxic epidermal necrolysis (Lyell's syndrome), Stevens-Johnson syndrome; frequency unknown - acute generalized eczematous pustulosis.
From the respiratory system: often - a decrease in sensitivity in the oral cavity or pharynx; rarely - dryness of the mucous membrane of the respiratory tract, rhinorrhea; in isolated cases - dryness of the mucous membrane of the pharynx.
At a temperature not exceeding 30 ° C. Keep out of the reach of children.
- Dosage form
- 30 mg
- Number of tablets
- INN Russian
- Russian title